metaEvidence - overview

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			DCR
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population
versus Standard of Care (SoC)
	durvalumab alone vs. Standard of Care (SoC)	1
	durvalumab plus tremelimumab vs. Standard of Care (SoC)	1
	nivolumab alone vs. Standard of Care (SoC)	1	-
	pembrolizumab alone vs. Standard of Care (SoC)	1	-